Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorocholine (18F)
- Development stage
- Unknown
- Lead developer
- Synektik
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Fluorocholine (18F) Synektik is a radiopharmaceutical diagnostic imaging agent used in positron emission tomography (PET). As a radioactive analog of choline, it is taken up by cells via choline transporters and phosphorylated by the enzyme choline kinase into 18F-phosphorylcholine, which becomes trapped within the cell membrane phospholipid synthesis pathway. Because malignant cells, such as those in prostate cancer and hepatocellular carcinoma, often exhibit upregulated choline metabolism to support rapid membrane synthesis and proliferation, the tracer accumulates preferentially in these tissues. This allows for the PET-based detection and localization of primary tumors and metastases, particularly bone metastases in patients with prostate cancer. The product is developed and manufactured by the Polish company Synektik.
- Brand names
- Fluorocholine (18F) Synektik
- Other names
- 18F-fluorocholine[18F]fluorocholinefluorocholine F-18FCH
02
Targets
CHKA (Choline kinase)CHT1 (High-affinity choline transporter 1)
Beyond the preview
Go deeper on fluorocholine (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorocholine (18F).